New trial
Phase III Study: Rilvegostomig Combinations in First-line Advanced HCC
- Trial ID
- NCT06921785 on ClinicalTrials.gov
- Cancer type
- Primary Hepatocellular Carcinoma (Liver, HCC)
- Location
- 46 Locations
- Published in
- New in Oncology - May 14, 2025
AstraZeneca is evaluating whether rilvegostomig combined with bevacizumab—with or without tremelimumab—can improve outcomes compared to atezolizumab plus bevacizumab in patients with unresectable advanced hepatocellular carcinoma.
More in liver and bile duct cancer
-
New trial · Sep 17, 2026 · NCT07793253
Phase 2 daraxonrasib pan-RAS(ON) tri-complex inhibitor targets KRAS-mutant biliary tract cancer. -
Trial result · Sep 10, 2026 · NCT05301842
STRIDE (durvalumab + tremelimumab) + VEGFR/FGFR TKI lenvatinib + TACE extends PFS in embolisation-eligible HCC -
New trial · Sep 10, 2026 · NCT07780838
Phase 2a pemigatinib FGFR1/2/3 inhibitor alternated with durvalumab PD‑L1 blockade -
New trial · Sep 3, 2026 · NCT07766187
Phase 2 durvalumab PD-L1 inhibitor plus histotripsy non-thermal focused ultrasound ablation in iCCA -
New trial · Aug 27, 2026 · NCT07723534
Phase 2 zolbetuximab CLDN18.2-directed monoclonal antibody + CAPOX/mFOLFOX6 in BTC